About the Study: This study found that nirsevimab was associated with a substantial reduction in RSV-LRTI–related hospitalizations during the first year across both the 2023-2024 and 2024-2025 seasons. It was not associated with reduced hospitalizations due to non-RSV infections or asthma, nor during the second year of follow-up.
Corresponding Author: Amélie Gabet, PhD, Department of Epidemiology and Health Product (EPI-PHARE), French National Agency for Medicines and Health Products Safety and French National Health Insurance (ANSM), 143 Boulevard Anatole France, 93285 Saint-Denis Cedex, France (amelie.gabet@ansm.sante.fr).
10.1001/jamapediatrics.2026.3384
To access the embargoed study: Visit our JAMA Network Media Center at this link https://media.jamanetwork.com/
Link to the article in your story
We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)
Editor's Note: Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
Journal
JAMA Pediatrics